

Attorney Docket No: 23546-07664
Client Ref: RTS-0266
USSN: 09/960,143

AMENDMENTS TO THE CLAIMS

1. (CURRENTLY AMENDED) A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human interleukin 8 (SEQ ID NO:3), wherein said compound specifically hybridizes with a region within nucleotides 391 through 1639 of said nucleic acid molecule encoding human interleukin 8 and inhibits the expression of human interleukin 8.
2. (Original) The compound of claim 1 which is an antisense oligonucleotide.
3. (Cancelled).
4. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. (Original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (Original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. (Original) The compound of claim 8, wherein the modified nucleobase is a 5-methylcytosine.
10. (Original) A compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11. (CURRENTLY AMENDED) A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site within nucleotides 391 through 1639 of on a nucleic acid molecule encoding human interleukin 8 (SEQ ID NO:3).

Attorney Docket No: 23546-07664
Client Ref: RTS-0266
USSN: 09/960,143

~~wherein said compound specifically hybridizes with nucleotides 391 through 1639 of said nucleic acid molecule encoding human interleukin 8.~~

12. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.

14. (Original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.

15. (CURRENTLY AMENDED) A method of inhibiting the expression of interleukin 8 in cells in cell culture or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of interleukin 8 is inhibited.

16. (CANCELED)

17. (CANCELED)

18. (CANCELED)

19. (CANCELED).

20. (CANCELED)

21. (previously presented) The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 52, 53, 54, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, or 69.

22-27. (Cancelled)

28. (NEW) An antisense oligonucleotide 20 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human interleukin 8 (SEQ ID NO:3), wherein said compound specifically hybridizes with a region within nucleotides 391 through 1639 of said nucleic acid

Attorney Docket No: 23546-07664
Client Ref: RTS-0266
USSN: 09/960,143

molecule encoding human interleukin 8 and inhibits the expression of human interleukin 8, wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 58.

29. (NEW) The antisense oligonucleotide of claim 28 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

30. (NEW) The antisense oligonucleotide of claim 29 wherein the modified internucleoside linkage is a phosphorothioate linkage.

31. (NEW) The antisense oligonucleotide of claim 28 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

32. (NEW) The antisense oligonucleotide of claim 31 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

33. (NEW) The antisense oligonucleotide of claim 28 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

34. (NEW) The antisense oligonucleotide of claim 33, wherein the modified nucleobase is a 5-methylcytosine.

35. (NEW) The antisense oligonucleotide of claim 28 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

36. (NEW) A composition comprising the antisense oligonucleotide of claim 28 and a pharmaceutically acceptable carrier or diluent.

37. (NEW) The composition of claim 36 further comprising a colloidal dispersion system.

38. (NEW) A method of inhibiting the expression of interleukin 8 in cells in cell culture comprising contacting said cells with the antisense oligonucleotide of claim 28 so that expression of interleukin 8 is inhibited.